P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY

por Short, Nicholas, Macaron, Walid, Dinardo, Courtney, Daver, Naval, Yilmaz, Musa, Borthakur, Gautam, Montalban-Bravo, Guillermo, Garcia-Manero, Guillermo, Issa, Ghayas, Sasaki, Koji, Burger, Jan, Maiti, Abhishek, Alvarado, Yesid, Thankachan, Jennifer, Abramova, Regina, Nasr, Lewis, Nasnas, Cedric, Zoghbi, Marianne, Kadia, Tapan, Konopleva, Marina, Kantarjian, Hagop, Ravandi, Farhad
Publicado 2023

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

por Short, Nicholas J., Muftuoglu, Muharrem, Ong, Faustine, Nasr, Lewis, Macaron, Walid, Montalban-Bravo, Guillermo, Alvarado, Yesid, Basyal, Mahesh, Daver, Naval, Dinardo, Courtney D., Borthakur, Gautam, Jain, Nitin, Ohanian, Maro, Jabbour, Elias, Issa, Ghayas C., Qiao, Wei, Huang, Xuelin, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Bose, Prithviraj, Ravandi, Farhad, Delumpa, Ricardo, Abramova, Regina, Garcia-Manero, Guillermo, Andreeff, Michael, Cortes, Jorge, Kantarjian, Hagop
Publicado 2023